You are here

CLL

TG Therapeutics completes FDA filing for Roche challenger in CLL

TG Therapeutics completes FDA filing for Roche challenger in CLL

Pharmaforum

TG Therapeutics

ublituximab-umbralisib

Flag link:

AZ says Calquence is a safer drug than Imbruvica

AZ says Calquence is a safer drug than Imbruvica

Pharmaforum

Flag link:

TG Therapeutics set for upsized IPO to develop cancer combination drug

TG Therapeutics set for upsized IPO to develop cancer combination drug

Pharmaforum

TG Therapeutics

Flag link:

ASH: AstraZeneca's Calquence, BeiGene's Brukinsa turn heads with new data, putting Imbruvica on notice

ASH: AstraZeneca's Calquence, BeiGene's Brukinsa turn heads with new data, putting Imbruvica on notice

Fierce Pharma

Flag link:

Janssen gets expanded EC nod for blood cancer combo drug Imbruvica plus rituximab

Janssen gets expanded EC nod for blood cancer combo drug Imbruvica plus rituximab

Pharmaceutical Business Review

Flag link:

AbbVie, J&J blockbuster Imbruvica rakes in 11th FDA approval, as competitors work on eroding franchise

AbbVie, J&J blockbuster Imbruvica rakes in 11th FDA approval, as competitors work on eroding franchise

Endpoints

Flag link:

Janssen seeks EMA nod for Imbruvica, rituximab combo in previously untreated CLL

Janssen seeks EMA nod for Imbruvica, rituximab combo in previously untreated CLL

Pharmaceutical Business Review

Flag link:

Leukemia rivals try to stay ahead as Merck, Lilly chase

Leukemia rivals try to stay ahead as Merck, Lilly chase

Biopharma Dive

Flag link:

ASH: Eli Lilly plots 'ambitious' cancer program after sharing early BTK data

ASH: Eli Lilly plots 'ambitious' cancer program after sharing early BTK data

Fierce Biotech

Flag link:

ASH19: AZ’s Calquence throws gauntlet down to Imbruvica

ASH19: AZ’s Calquence throws gauntlet down to Imbruvica

Pharmaforum

Flag link:

ASH: AbbVie, Roche pad their case for fixed-duration Venclexta use in CLL

ASH: AbbVie, Roche pad their case for fixed-duration Venclexta use in CLL

Fierce Pharma

Flag link:

AstraZeneca's Calquence Wins FDA Approval for Chronic Lymphocytic Leukemia

AstraZeneca's Calquence Wins FDA Approval for Chronic Lymphocytic Leukemia

BioSpace

Flag link:

AstraZeneca's Calquence steps up to challenge Imbruvica with big CLL green light

AstraZeneca's Calquence steps up to challenge Imbruvica with big CLL green light

Fierce Pharma

Flag link:

AbbVie submits sNDA to FDA for IMBRUVICA, Rituximab combo for CLL

AbbVie submits sNDA to FDA for IMBRUVICA, Rituximab combo for CLL

Pharmaceutical Business Review

Flag link:

AstraZeneca Has Dazzled in Recent Cancer Trials, but Faces Stiff Competition

AstraZeneca Has Dazzled in Recent Cancer Trials, but Faces Stiff Competition

BioSpace

clinical trials

extensive-stage small cell lung cancer

Flag link:

AstraZeneca's Calquence sets Imbruvica in its sights with big CLL survival numbers

AstraZeneca's Calquence sets Imbruvica in its sights with big CLL survival numbers

Fierce Pharma

Flag link:

AstraZeneca ends another Calquence trial early

AstraZeneca ends another Calquence trial early

Pharmaforum

clinical trials

Flag link:

AbbVie, Roche snag another CLL nod, this time for Venclexta-Gazyva

AbbVie, Roche snag another CLL nod, this time for Venclexta-Gazyva

Fierce Pharma

small lymphocytic leukemia

Flag link:

ASH successes set to lift Imbruvica in CLL

ASH successes set to lift Imbruvica in CLL

Biopharma Dive

Flag link:

ASH18: CAR-T shows up in early CLL test

ASH18: CAR-T shows up in early CLL test

Biopharma Dive

Flag link:

Pages